Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 4698: A bill to amend the Federal Food, Drug, and Cosmetic Act to authorize the use of investigational individualized medical treatments by patients diagnosed with a life-threatening disease or condition or severely debilitating illness, and for other purposes.”

Read twice and referred to the Committee on Finance.

Original title: “S 2149: Health Equity and Access under the Law for Immigrant Families Act of 2025”

Referred to the Subcommittee on Intellectual Property, Competition and the Internet.

Original title: “HR 1150: Competitive Health Insurance Reform Act of 2011”

Referred to the Subcommittee on Intellectual Property, Competition and the Internet.

Original title: “HR 1888: Promoting American Agricultural and Medical Exports to Cuba Act of 2011”

Referred to the Subcommittee on Intellectual Property, Competition and the Internet.

Original title: “HR 1943: Health Insurance Industry Fair Competition Act”

Subcommittee Hearings Held.

Original title: “HR 1946: Preserving Our Hometown Independent Pharmacies Act of 2011”

Referred to the Subcommittee on Intellectual Property, Competition and the Internet.

Original title: “HR 5838: Health Insurance Industry Antitrust Enforcement Act of 2012”

The Office of Child Support Enforcement proposes to rescind the Employment and Training Services for Noncustodial Parents in the Child Support Program final rule, published in the Federal Register on December 13, 2024. The final rule allowed child support agencies to utilize Federal Financial Participation under title IV-D of the Social Security Act for providing specific, optional, and non-duplicative employment and training services to eligible noncustodial parents.

Original title: “Employment and Training Services for Noncustodial Parents in the Child Support Program; Rescission”

This Final Rule amends the Block Grants regulations, the Individual Development Account Reserve Funds Established Pursuant to Grants for Assets for Independence regulations, and the Emergency Community Services Homeless Grant Program regulations to eliminate unnecessary or obsolete regulations. A plain language summary of this final rule is posted at https://www.regulations.gov.

Original title: “Reducing Bureaucracy and Burden for Community Services Programs”

Ordered to be Reported (Amended) by the Yeas and Nays: 18 - 15.

Original title: “HR 9228: Health Data Access, Transparency, and Affordability Act of 2026”

Original title: “Office of the Director; Notice of Charter Renewal”

The FDA has expanded the regulatory toolkit during President Donald Trump’s second term, adding new mechanisms for rare diseases while putting the Biden-era platform technology designation into action.

Original title: “Busy FDA gives rare disease sector complementary pathways, unanswered questions”

As the FDA tries to clarify its intent for former FDA Commissioner Marty Makary’s plausible mechanism framework for bespoke therapies, experts emphasize the importance of expanding its scope to encompass rare diseases that affect more than just one or a few individuals.

Original title: “Post-Makary, new rare disease framework faces fresh uncertainty”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 9169: To support polycystic kidney disease research, and for other purposes.”

Referred to the House Committee on Armed Services.

Original title: “HR 9140: To require the Secretary of Defense and the Secretary of Homeland Security to improve the transition of medics into the civilian workforce in certain health care occupations and to modify the assistance provided to separated members of the Armed Forces seeking employment with health care providers, and for other purposes.”

Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 9040: Regulate the Price of All Drugs Act”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 9065: Pregnancy Loss Mental Health Research Act of 2026”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 9077: Hormone Health Data and Research Act”

The Administration for Children and Families (ACF) is requesting Office of Management and Budget (OMB) to reinstate approval of the ACF-700: Tribal Annual Report (OMB #0970-0430) with proposed revisions. ACF requests changes to the form that reduce annual burden hours.

Original title: “Proposed Information Collection Activity; ACF-700 Tribal Annual Report”

The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.

Original title: “Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness”